Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
- 1 November 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 140, 11-18
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
- National Cancer Institute
This publication has 25 references indexed in Scilit:
- Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literatureClinical Epidemiology, 2016
- Critical Assessment of Clinical Prognostic Tools in MelanomaAnnals of Surgical Oncology, 2016
- Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous MelanomaJournal of Clinical Oncology, 2015
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsyJournal of the American Academy of Dermatology, 2015
- The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanomaMelanoma Research, 2015
- More People Die from Thin Melanomas (≤1 mm) than from Thick Melanomas (>4 mm) in Queensland, AustraliaJournal of Investigative Dermatology, 2015
- Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark’s level of invasion: results of a population-based study from the Swedish Melanoma RegisterBritish Journal of Dermatology, 2012
- Melanoma Thickness Trends in the United States, 1988–2006Journal of Investigative Dermatology, 2010
- A protocol for building and evaluating predictors of disease state based on microarray dataBioinformatics, 2005